Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
Circulation. Arrhythmia and Electrophysiology|January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) TrialAn H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.
American Heart Journal|March 30, 2013
The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical developmentAdel Nada, Gary A Gintant, Robert Kleiman, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure|April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programmeNathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
American Heart Journal|July 15, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
American Heart Journal|June 22, 2015
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research ConsortiumSimon Heller, Börje Darpö, Malcolm I Mitchell, et al.
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
Pageof 19